Arthritis, Psoriatic News and Research

RSS
Price check on drug ads: Would revealing costs help patients control spending?

Price check on drug ads: Would revealing costs help patients control spending?

Researchers discover link between rheumatoid arthritis and bacteria in milk

Researchers discover link between rheumatoid arthritis and bacteria in milk

Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

Zydus Cadila becomes world's first company to launch biosimilar of Adalimumab

Zydus Cadila becomes world's first company to launch biosimilar of Adalimumab

Covagen begins COVA322 Phase Ib/IIa study to treat patients with rheumatoid and psoriatic arthritis

Covagen begins COVA322 Phase Ib/IIa study to treat patients with rheumatoid and psoriatic arthritis

Anti-tumor necrosis factor drugs modestly reduce risk of acute coronary syndrome

Anti-tumor necrosis factor drugs modestly reduce risk of acute coronary syndrome

Simponi injection gets FDA approval to treat adults with ulcerative colitis

Simponi injection gets FDA approval to treat adults with ulcerative colitis

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

Johnson & Johnson third quarter sales increase 6.8% to $16.0 billion

Johnson & Johnson third quarter sales increase 6.8% to $16.0 billion

HealthWell Foundation introduces new lupus fund

HealthWell Foundation introduces new lupus fund

Johnson & Johnson reports net sales of $16.2 billion for first quarter 2011

Johnson & Johnson reports net sales of $16.2 billion for first quarter 2011

Important updates on spondyloarthritis highlighted at 2010 SPARTAN meeting

Important updates on spondyloarthritis highlighted at 2010 SPARTAN meeting

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

Merck's SIMPONI anti-TNF therapy now reimbursed in New Brunswick, Nova Scotia and Alberta

Merck's SIMPONI anti-TNF therapy now reimbursed in New Brunswick, Nova Scotia and Alberta

Johnson & Johnson second-quarter sales increase 0.6% to $15.3 billion

Johnson & Johnson second-quarter sales increase 0.6% to $15.3 billion

Alcohol consumption associated with reduced risk of developing several arthritic conditions: Study

Alcohol consumption associated with reduced risk of developing several arthritic conditions: Study

Johnson & Johnson' first-quarter 2010 sales increase 4.0% to $15.6 billion

Johnson & Johnson' first-quarter 2010 sales increase 4.0% to $15.6 billion

Health Canada approves Simponi (golimumab) for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

Health Canada approves Simponi (golimumab) for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

FDA forces manufacturers of TNF-blockers to highlight risk of fungal infections

FDA forces manufacturers of TNF-blockers to highlight risk of fungal infections